Skip to content
Disclosery

Birchview Capital, LP

Follow

13F filer, CIK 1618205, BURLINGTON, VT

Birchview Capital, LP reported $213,828,198 across 72 holdings for the quarter ended 2026-06-30, in a 13F-HR filed 2026-08-14. Its ten largest share positions make up 59.94% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001618205-26-000003

Period
2026-06-30
Reported value
$214M
Holdings
72
Top 10 weight
59.94%
New
14
Sold out
15

Largest buys vs the previous quarter

SecurityShares changeApprox. value
KLACadded+158,588$47.8M
NKTRadded+50,000$3.49M
ABVXnew+17,000$2.27M
VIRnew+220,000$2.24M
HALOadded+23,151$1.81M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
CMPSreduced-345,000-$4.88M
GPCRreduced-76,000-$4.08M
OCULreduced-299,345-$2.94M
QUREreduced-50,000-$2.3M
NVCRexited-202,330-$2.21M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2026

Share positions as resolved from 13F-HR 0001618205-26-000003, largest first. % of portfolio is the value over $213,828,198, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
KLACKLA CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 15,848 shares; 2025Q3: 21,883 shares; 2025Q4: 21,883 shares; 2026Q1: 19,883 shares; 2026Q2: 178,471 shares 178,471$53.8M25.18%+158,588Timeline
BMYBRISTOL-MYERS SQUIBB COQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 686,182 shares; 2024Q4: 685,182 shares; 2025Q1: 685,192 shares; 2025Q2: 323,358 shares; 2025Q3: 316,842 shares; 2025Q4: 302,842 shares; 2026Q1: 306,268 shares; 2026Q2: 297,243 shares 297,243$17.1M8.01%-9,025Timeline
LRCXLAM RESEARCH CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 40,329 shares; 2026Q1: 36,000 shares; 2026Q2: 35,000 shares 35,000$15.2M7.09%-1,000Timeline
NTLAINTELLIA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 60,000 shares; 2025Q3: 60,000 shares; 2025Q4: 315,400 shares; 2026Q1: 445,400 shares; 2026Q2: 385,900 shares 385,900$6.78M3.17%-59,500Timeline
SLDBSOLID BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 128,768 shares; 2025Q2: 178,768 shares; 2025Q3: 296,955 shares; 2025Q4: 705,955 shares; 2026Q1: 625,980 shares; 2026Q2: 666,196 shares 666,196$6.66M3.11%+40,216Timeline
BIODESIX INCBIODESIX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 5,696,113 shares; 2024Q4: 5,736,113 shares; 2025Q1: 5,736,113 shares; 2025Q2: 5,736,113 shares; 2025Q3: 286,804 shares; 2025Q4: 286,804 shares; 2026Q1: 286,804 shares; 2026Q2: 286,804 shares 286,804$6.47M3.02%0
STOKSTOKE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 210,000 shares; 2024Q4: 210,000 shares; 2025Q1: 210,005 shares; 2025Q2: 210,000 shares; 2025Q3: 210,000 shares; 2025Q4: 260,000 shares; 2026Q1: 210,000 shares; 2026Q2: 178,110 shares 178,110$5.83M2.73%-31,890Timeline
OVVOVINTIV INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 52,200 shares; 2024Q4: 52,200 shares; 2025Q1: 52,200 shares; 2025Q2: 107,500 shares; 2025Q3: 107,500 shares; 2025Q4: 107,500 shares; 2026Q1: 107,500 shares; 2026Q2: 107,500 shares 107,500$5.66M2.65%0Timeline
NKTRNEKTAR THERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 4,021 shares; 2025Q4: 31,000 shares; 2026Q1: 31,000 shares; 2026Q2: 81,000 shares 81,000$5.65M2.64%+50,000Timeline
CORTCORCEPT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 74,000 shares; 2024Q4: 74,000 shares; 2025Q1: 66,000 shares; 2025Q2: 67,200 shares; 2025Q3: 67,200 shares; 2025Q4: 67,200 shares; 2026Q1: 47,200 shares; 2026Q2: 57,200 shares 57,200$4.97M2.33%+10,000Timeline
NBIXNEUROCRINE BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 30,240 shares; 2024Q4: 30,240 shares; 2025Q1: 30,240 shares; 2025Q2: 30,940 shares; 2025Q3: 28,690 shares; 2025Q4: 27,190 shares; 2026Q1: 27,190 shares; 2026Q2: 27,190 shares 27,190$4.58M2.14%0Timeline
PRTAPROTHENA CORP PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 209,574 shares; 2024Q4: 304,574 shares; 2025Q1: 332,974 shares; 2025Q2: 451,019 shares; 2025Q3: 549,019 shares; 2025Q4: 441,019 shares; 2026Q1: 449,019 shares; 2026Q2: 449,019 shares 449,019$4.4M2.06%0Timeline
ACADACADIA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 400,400 shares; 2024Q4: 338,400 shares; 2025Q1: 263,400 shares; 2025Q2: 187,800 shares; 2025Q3: 171,000 shares; 2025Q4: 171,000 shares; 2026Q1: 171,000 shares; 2026Q2: 171,000 shares 171,000$4.33M2.02%0Timeline
PTGXPROTAGONIST THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 48,000 shares; 2024Q4: 48,000 shares; 2025Q1: 48,002 shares; 2025Q2: 48,000 shares; 2025Q3: 48,000 shares; 2025Q4: 55,000 shares; 2026Q1: 35,000 shares; 2026Q2: 35,018 shares 35,018$4.29M2.01%+18Timeline
CMPXCOMPASS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 24,000 shares; 2025Q2: not reported; 2025Q3: 872,938 shares; 2025Q4: 1,592,938 shares; 2026Q1: 1,465,867 shares; 2026Q2: 1,675,000 shares 1,675,000$3.67M1.72%+209,133Timeline
RLMDRELMADA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 409,387 shares; 2026Q2: 408,100 shares 408,100$2.82M1.32%-1,287Timeline
ALKSALKERMES PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 50,000 shares; 2024Q4: 50,000 shares; 2025Q1: 50,000 shares; 2025Q2: 50,000 shares; 2025Q3: 50,000 shares; 2025Q4: 50,000 shares; 2026Q1: 50,000 shares; 2026Q2: 50,000 shares 50,000$2.62M1.23%0Timeline
HALOHALOZYME THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 10,000 shares; 2024Q4: 10,000 shares; 2025Q1: 10,000 shares; 2025Q2: 10,000 shares; 2025Q3: 10,100 shares; 2025Q4: 10,100 shares; 2026Q1: 10,100 shares; 2026Q2: 33,251 shares 33,251$2.6M1.22%+23,151Timeline
CLDXCELLDEX THERAPEUTICS INC NEWQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 70,095 shares; 2026Q2: 69,900 shares 69,900$2.6M1.22%-195Timeline
CYTKCYTOKINETICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 10,000 shares; 2024Q4: 10,000 shares; 2025Q1: 10,000 shares; 2025Q2: 10,000 shares; 2025Q3: 30,000 shares; 2025Q4: 30,000 shares; 2026Q1: 30,000 shares; 2026Q2: 30,000 shares 30,000$2.56M1.2%0Timeline
OLMAOLEMA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 134,000 shares; 2025Q3: 174,000 shares; 2025Q4: 269,000 shares; 2026Q1: 219,000 shares; 2026Q2: 199,000 shares 199,000$2.49M1.16%-20,000Timeline
VERAVERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 44,000 shares; 2026Q1: 44,000 shares; 2026Q2: 57,758 shares 57,758$2.48M1.16%+13,758Timeline
UTHRUNITED THERAPEUTICS CORP DELQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 10,000 shares; 2024Q4: 10,000 shares; 2025Q1: 7,500 shares; 2025Q2: 4,250 shares; 2025Q3: 3,000 shares; 2025Q4: 3,000 shares; 2026Q1: 4,500 shares; 2026Q2: 4,506 shares 4,506$2.44M1.14%+6Timeline
ZBIOZENAS BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: 16,500 shares; 2025Q1: 16,500 shares; 2025Q2: 16,500 shares; 2025Q3: 16,500 shares; 2025Q4: not reported; 2026Q1: 70,000 shares; 2026Q2: 93,601 shares 93,601$2.38M1.11%+23,601Timeline
QUREUNIQURE NVQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 20,000 shares; 2024Q4: 20,000 shares; 2025Q1: 88,697 shares; 2025Q2: 98,697 shares; 2025Q3: 78,728 shares; 2025Q4: 30,789 shares; 2026Q1: 100,697 shares; 2026Q2: 50,697 shares 50,697$2.34M1.09%-50,000Timeline
PACBPACIFIC BIOSCIENCES CALIF INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 400,000 shares; 2025Q3: 500,000 shares; 2025Q4: 500,000 shares; 2026Q1: 1,500,000 shares; 2026Q2: 1,350,000 shares 1,350,000$2.27M1.06%-150,000Timeline
ABVXABIVAX SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 17,000 shares 17,000$2.27M1.06%newTimeline
VIRVIR BIOTECHNOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 220,000 shares 220,000$2.24M1.05%newTimeline
BIIBBIOGEN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 5,000 shares; 2026Q2: 9,000 shares 9,000$1.94M0.91%+4,000Timeline
EQTEQT CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 34,619 shares; 2024Q4: 34,619 shares; 2025Q1: 34,619 shares; 2025Q2: 34,619 shares; 2025Q3: 34,619 shares; 2025Q4: 34,619 shares; 2026Q1: 34,619 shares; 2026Q2: 34,619 shares 34,619$1.84M0.86%0Timeline
BIOABIOAGE LABS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 69,000 shares 69,000$1.69M0.79%newTimeline
TVTXTRAVERE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 148,000 shares; 2024Q4: 148,000 shares; 2025Q1: 138,000 shares; 2025Q2: 103,000 shares; 2025Q3: 43,060 shares; 2025Q4: 43,000 shares; 2026Q1: 29,200 shares; 2026Q2: 29,000 shares 29,000$1.65M0.77%-200Timeline
QUIDEL CORPQUIDEL CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 67,619 shares; 2024Q4: 67,619 shares; 2025Q1: 67,619 shares; 2025Q2: 72,548 shares; 2025Q3: 72,548 shares; 2025Q4: 72,548 shares; 2026Q1: 82,548 shares; 2026Q2: 89,377 shares 89,377$1.57M0.73%+6,829
AXSMAXSOME THERAPEUTICS INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 4,000 shares; 2024Q4: 4,000 shares; 2025Q1: 6,000 shares; 2025Q2: 6,000 shares; 2025Q3: 6,000 shares; 2025Q4: 6,061 shares; 2026Q1: 6,000 shares; 2026Q2: 6,000 shares 6,000$1.47M0.69%0Timeline
FHTXFOGHORN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 320,930 shares; 2024Q4: 310,930 shares; 2025Q1: 310,930 shares; 2025Q2: 310,930 shares; 2025Q3: 281,730 shares; 2025Q4: 281,730 shares; 2026Q1: 281,730 shares; 2026Q2: 281,937 shares 281,937$1.38M0.64%+207Timeline
BCYCBICYCLE THERAPEUTICS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 154,000 shares; 2025Q4: 462,700 shares; 2026Q1: 463,599 shares; 2026Q2: 313,616 shares 313,616$1.33M0.62%-149,983Timeline
GPCRSTRUCTURE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 36,000 shares; 2025Q3: 78,000 shares; 2025Q4: 90,000 shares; 2026Q1: 100,000 shares; 2026Q2: 24,000 shares 24,000$1.29M0.6%-76,000Timeline
XENEXENON PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 10,000 shares; 2024Q4: 10,000 shares; 2025Q1: 21,000 shares; 2025Q2: 21,000 shares; 2025Q3: 21,000 shares; 2025Q4: 21,000 shares; 2026Q1: 21,000 shares; 2026Q2: 21,032 shares 21,032$1.27M0.59%+32Timeline
NVONOVO-NORDISK A SQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 24,000 shares 24,000$1.15M0.54%newTimeline
FCXFREEPORT MCMORAN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 18,033 shares; 2025Q3: 18,044 shares; 2025Q4: 18,046 shares; 2026Q1: 18,040 shares; 2026Q2: 18,035 shares 18,035$1.13M0.53%-5Timeline
IMNMIMMUNOME INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 60,000 shares; 2025Q3: 105,000 shares; 2025Q4: 130,000 shares; 2026Q1: 50,000 shares; 2026Q2: 50,000 shares 50,000$1.06M0.5%0Timeline
PHVSPHARVARIS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 14,847 shares; 2025Q4: 29,847 shares; 2026Q1: 29,847 shares; 2026Q2: 29,847 shares 29,847$1.03M0.48%0Timeline
HROWHARROW INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 72,910 shares; 2024Q4: 72,910 shares; 2025Q1: 72,910 shares; 2025Q2: 60,000 shares; 2025Q3: 40,000 shares; 2025Q4: 34,000 shares; 2026Q1: 24,000 shares; 2026Q2: 24,000 shares 24,000$1.02M0.48%0Timeline
ADAGADAGENE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 240,000 shares 240,000$1.01M0.47%newTimeline
DFTXDEFINIUM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 20,000 shares 20,000$941K0.44%newTimeline
SLNSILENCE THERAPEUTICS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 71,218 shares 71,218$782K0.37%newTimeline
BBIOBRIDGEBIO PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 5,000 shares; 2025Q3: 8,688 shares; 2025Q4: 8,688 shares; 2026Q1: 8,688 shares; 2026Q2: 8,741 shares 8,741$651K0.3%+53Timeline
FDMT4D MOLECULAR THERAPEUTICS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 48,505 shares 48,505$645K0.3%newTimeline
URGNUROGEN PHARMA LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 16,487 shares 16,487$607K0.28%newTimeline
PHATPHATHOM PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 25,000 shares; 2025Q3: 85,000 shares; 2025Q4: 195,000 shares; 2026Q1: 195,000 shares; 2026Q2: 55,000 shares 55,000$597K0.28%-140,000Timeline
CAMPCAMP4 THERAPEUTICS CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 120,000 shares 120,000$524K0.25%newTimeline
SVRASAVARA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 80,000 shares 80,000$493K0.23%newTimeline
CADLCANDEL THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: 60,000 shares; 2025Q1: 60,000 shares; 2025Q2: 60,000 shares; 2025Q3: 60,000 shares; 2025Q4: 60,000 shares; 2026Q1: 60,000 shares; 2026Q2: 47,756 shares 47,756$492K0.23%-12,244Timeline
ALTALTIMMUNE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 152,681 shares 152,681$464K0.22%newTimeline
CMPSCOMPASS PATHWAYS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 375,000 shares; 2026Q2: 30,000 shares 30,000$424K0.2%-345,000Timeline
KARYOPHARM THERAPEUTICS INCKARYOPHARM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 469,832 shares; 2024Q4: 419,832 shares; 2025Q1: 27,985 shares; 2025Q2: 27,985 shares; 2025Q3: 27,985 shares; 2025Q4: not reported; 2026Q1: 83,952 shares; 2026Q2: 42,952 shares 42,952$420K0.2%-41,000
CGEMCULLINAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 20,000 shares; 2024Q4: 20,000 shares; 2025Q1: 20,000 shares; 2025Q2: 20,000 shares; 2025Q3: 20,000 shares; 2025Q4: 20,000 shares; 2026Q1: 20,000 shares; 2026Q2: 20,000 shares 20,000$364K0.17%0Timeline
TRINTRINITY CAP INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 20,000 shares; 2026Q1: 20,000 shares; 2026Q2: 20,000 shares 20,000$358K0.17%0Timeline
CAPRCAPRICOR THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 14,352 shares 14,352$346K0.16%newTimeline
CSTLCASTLE BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 58,000 shares; 2024Q4: 78,000 shares; 2025Q1: 88,404 shares; 2025Q2: 110,600 shares; 2025Q3: 110,600 shares; 2025Q4: 80,600 shares; 2026Q1: 12,900 shares; 2026Q2: 12,984 shares 12,984$310K0.14%+84Timeline
IVVDINVIVYD INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 342,275 shares 342,275$299K0.14%newTimeline
GRCEGRACE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 50,000 shares; 2026Q2: 120,000 shares 120,000$272K0.13%+70,000Timeline
KBDCKAYNE ANDERSON BDC INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 20,000 shares; 2026Q1: 20,000 shares; 2026Q2: 20,000 shares 20,000$271K0.13%0Timeline
VYGRVOYAGER THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 134,918 shares; 2025Q4: 74,918 shares; 2026Q1: 74,918 shares; 2026Q2: 75,147 shares 75,147$263K0.12%+229Timeline
LUNGPULMONX CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: 51,000 shares; 2025Q1: 51,000 shares; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 250,573 shares; 2026Q1: 250,221 shares; 2026Q2: 200,543 shares 200,543$261K0.12%-49,678Timeline
OCULOCULAR THERAPEUTIX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 320,000 shares; 2026Q2: 20,655 shares 20,655$203K0.09%-299,345Timeline
KYNBKYNTRA BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 22,566 shares; 2026Q2: 22,566 shares 22,566$170K0.08%0Timeline
ELUTELUTIA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 1,321,215 shares; 2024Q4: 1,225,489 shares; 2025Q1: 1,187,735 shares; 2025Q2: 1,159,059 shares; 2025Q3: 711,175 shares; 2025Q4: 263,018 shares; 2026Q1: 165,094 shares; 2026Q2: 165,094 shares 165,094$162K0.08%0Timeline
QNRXQUOIN PHARMACEUTICALS LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 20,000 shares; 2026Q2: 20,000 shares 20,000$96.8K0.05%0Timeline
LPCNLIPOCINE INC NEWQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 111,786 shares; 2026Q2: 16,712 shares 16,712$42.8K0.02%-95,074Timeline
DCGODOCGO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 515,000 shares; 2024Q4: 764,062 shares; 2025Q1: 864,062 shares; 2025Q2: 764,062 shares; 2025Q3: 764,062 shares; 2025Q4: 49,908 shares; 2026Q1: 39,573 shares; 2026Q2: 39,062 shares 39,062$20.2K0.01%-511Timeline
GOSSGOSSAMER BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 138,176 shares; 2024Q4: 138,176 shares; 2025Q1: 138,176 shares; 2025Q2: 138,176 shares; 2025Q3: 138,176 shares; 2025Q4: 138,176 shares; 2026Q1: 18,176 shares; 2026Q2: 18,176 shares 18,176$2.99K<0.01%0Timeline

Sold out in Q2 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
NVCRNOVOCURE LTD202,330$2.21Mshares
ENGNENGENE HOLDINGS INC250,000$1.7Mshares
RAREULTRAGENYX PHARMACEUTICAL IN62,000$1.3Mshares
KALVKALVISTA PHARMACEUTICALS INC57,000$1.15Mshares
VSTMVERASTEM INC150,000$795Kshares
APGEAPOGEE THERAPEUTICS INC9,000$758Kshares
APLSAPELLIS PHARMACEUTICALS INC14,000$563Kshares
IDYAIDEAYA BIOSCIENCES INC16,860$562Kshares
RCUSARCUS BIOSCIENCES INC25,889$559Kshares
RGNXREGENXBIO INC66,270$555Kshares
RCKTROCKET PHARMACEUTICALS INC127,025$455Kshares
VRDNVIRIDIAN THERAPEUTICS INC20,100$393Kshares
OUTSET MEDICAL INCOUTSET MEDICAL INC98,882$380Kshares
PHRPHREESIA INC14,300$120Kshares
ZNTLZENTALIS PHARMACEUTICALS INC17,503$41Kshares

How Q2 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001618205-26-000003 base2026-08-14acceptance time not in the bulk data set

Filings

Every filing of this filer: 13F reports and notices, the 13D and 13G it filed or is a reporting person of, and Forms 3, 4 and 5 it reported as an owner.

FilingSubjectFiledAcceptedIngested
13F-HR 0001618205-26-000003 Quarter ended 2026-06-302026-08-14acceptance time not in the bulk data set
13F-HR 0001618205-26-000002 Quarter ended 2026-03-312026-05-15acceptance time not in the bulk data set
13F-HR 0001618205-26-000001 Quarter ended 2025-12-312026-02-13acceptance time not in the bulk data set
13F-HR 0001618205-25-000011 Quarter ended 2025-09-302025-11-13acceptance time not in the bulk data set
13F-HR 0001618205-25-000009 Quarter ended 2025-06-302025-08-14acceptance time not in the bulk data set
13F-HR/A 0001618205-25-000003 Quarter ended 2023-09-302025-06-30acceptance time not in the bulk data set
13F-HR/A 0001618205-25-000004 Quarter ended 2023-12-312025-06-30acceptance time not in the bulk data set
13F-HR/A 0001618205-25-000007 Quarter ended 2024-09-302025-06-30acceptance time not in the bulk data set
13F-HR/A 0001618205-25-000005 Quarter ended 2024-03-312025-06-30acceptance time not in the bulk data set
13F-HR/A 0001618205-25-000006 Quarter ended 2024-06-302025-06-30acceptance time not in the bulk data set
13F-HR/A 0001618205-25-000008 Quarter ended 2024-12-312025-06-30acceptance time not in the bulk data set
13F-HR 0001618205-25-000002 Quarter ended 2025-03-312025-05-15acceptance time not in the bulk data set
13F-HR 0001618205-25-000001 Quarter ended 2024-12-312025-02-14acceptance time not in the bulk data set
13F-HR 0001618205-24-000004 Quarter ended 2024-09-302024-11-14acceptance time not in the bulk data set
13F-HR 0001618205-24-000003 Quarter ended 2024-06-302024-08-13acceptance time not in the bulk data set
13F-HR 0001618205-24-000002 Quarter ended 2024-03-312024-05-14acceptance time not in the bulk data set
13F-HR 0001618205-24-000001 Quarter ended 2023-12-312024-02-14acceptance time not in the bulk data set
13F-HR 0001618205-23-000005 Quarter ended 2023-09-302023-11-14acceptance time not in the bulk data set
13F-HR 0001618205-23-000004 Quarter ended 2023-06-302023-08-08acceptance time not in the bulk data set
13F-HR 0001618205-23-000002 Quarter ended 2023-03-312023-05-12acceptance time not in the bulk data set
13F-HR 0001618205-23-000001 Quarter ended 2022-12-312023-02-03acceptance time not in the bulk data set
13F-HR/A 0001618205-22-000005 Quarter ended 2022-09-302022-11-28acceptance time not in the bulk data set
13F-HR 0001618205-22-000004 Quarter ended 2022-09-302022-11-07acceptance time not in the bulk data set
13F-HR 0001618205-22-000003 Quarter ended 2022-06-302022-08-12acceptance time not in the bulk data set
13F-HR 0001618205-22-000002 Quarter ended 2022-03-312022-05-13acceptance time not in the bulk data set
13F-HR 0001618205-22-000001 Quarter ended 2021-12-312022-02-14acceptance time not in the bulk data set
13F-HR 0001618205-21-000004 Quarter ended 2021-09-302021-11-12acceptance time not in the bulk data set
13F-HR 0001618205-21-000003 Quarter ended 2021-06-302021-08-10acceptance time not in the bulk data set
13F-HR 0001618205-21-000002 Quarter ended 2021-03-312021-05-14acceptance time not in the bulk data set
13F-HR 0001618205-21-000001 Quarter ended 2020-12-312021-02-09acceptance time not in the bulk data set
13F-HR 0001618205-20-000006 Quarter ended 2020-09-302020-11-12acceptance time not in the bulk data set
13F-HR/A 0001618205-20-000007 Quarter ended 2020-09-302020-11-12acceptance time not in the bulk data set
13F-HR/A 0001618205-20-000004 Quarter ended 2020-06-302020-09-25acceptance time not in the bulk data set
13F-HR 0001618205-20-000003 Quarter ended 2020-06-302020-08-10acceptance time not in the bulk data set
13F-HR 0001618205-20-000002 Quarter ended 2020-03-312020-05-12acceptance time not in the bulk data set
13F-HR 0001618205-20-000001 Quarter ended 2019-12-312020-02-12acceptance time not in the bulk data set
13F-HR 0001618205-19-000006 Quarter ended 2019-09-302019-11-12acceptance time not in the bulk data set
13F-HR 0001618205-19-000004 Quarter ended 2019-06-302019-08-06acceptance time not in the bulk data set
13F-HR 0001618205-19-000002 Quarter ended 2019-03-312019-05-03acceptance time not in the bulk data set
13F-HR 0001618205-19-000001 Quarter ended 2018-12-312019-02-06acceptance time not in the bulk data set
13F-HR 0001618205-18-000006 Quarter ended 2018-09-302018-11-01acceptance time not in the bulk data set
13F-HR 0001618205-18-000005 Quarter ended 2018-06-302018-08-02acceptance time not in the bulk data set
13F-HR 0001618205-18-000003 Quarter ended 2018-03-312018-05-07acceptance time not in the bulk data set
13F-HR 0001618205-18-000001 Quarter ended 2017-12-312018-02-02acceptance time not in the bulk data set
13F-HR 0001618205-17-000004 Quarter ended 2017-09-302017-11-02acceptance time not in the bulk data set
13F-HR 0001618205-17-000003 Quarter ended 2017-06-302017-08-08acceptance time not in the bulk data set
13F-HR 0001618205-17-000002 Quarter ended 2017-03-312017-05-04acceptance time not in the bulk data set
13F-HR 0001618205-17-000001 Quarter ended 2016-12-312017-02-09acceptance time not in the bulk data set
13F-HR 0001618205-16-000017 Quarter ended 2016-09-302016-11-14acceptance time not in the bulk data set
13F-HR 0001618205-16-000016 Quarter ended 2016-06-302016-08-09acceptance time not in the bulk data set
13F-HR 0001618205-16-000014 Quarter ended 2016-03-312016-04-28acceptance time not in the bulk data set
13F-HR 0001618205-16-000012 Quarter ended 2015-12-312016-02-08acceptance time not in the bulk data set
13F-HR/A 0001618205-15-000010 Quarter ended 2015-09-302015-12-30acceptance time not in the bulk data set
13F-HR 0001603544-15-000005 Quarter ended 2015-09-302015-11-06acceptance time not in the bulk data set
13F-HR/A 0001603544-15-000006 Quarter ended 2015-09-302015-11-06acceptance time not in the bulk data set
13F-HR/A 0001618205-15-000007 Quarter ended 2015-06-302015-08-17acceptance time not in the bulk data set
13F-HR/A 0001618205-15-000006 Quarter ended 2015-06-302015-08-14acceptance time not in the bulk data set
13F-HR 0001618205-15-000005 Quarter ended 2015-06-302015-08-13acceptance time not in the bulk data set
13F-HR/A 0001618205-15-000002 Quarter ended 2014-12-312015-05-07acceptance time not in the bulk data set
13F-HR/A 0001618205-15-000003 Quarter ended 2015-03-312015-05-07acceptance time not in the bulk data set
13F-HR 0001603544-15-000004 Quarter ended 2015-03-312015-04-24acceptance time not in the bulk data set
13F-HR/A 0001603544-15-000003 Quarter ended 2014-12-312015-04-24acceptance time not in the bulk data set
13F-HR 0001618205-15-000001 Quarter ended 2014-12-312015-02-06acceptance time not in the bulk data set